Coherus Oncology (CHRS) EBIAT: 2013-2025
Historic EBIAT for Coherus Oncology (CHRS) over the last 12 years, with Sep 2025 value amounting to -$44.5 million.
- Coherus Oncology's EBIAT rose 6.47% to -$44.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $394.5 million, marking a year-over-year increase of 597.92%. This contributed to the annual value of $28.5 million for FY2024, which is 111.98% up from last year.
- Coherus Oncology's EBIAT amounted to -$44.5 million in Q3 2025, which was down 114.95% from $297.8 million recorded in Q2 2025.
- Coherus Oncology's 5-year EBIAT high stood at $297.8 million for Q2 2025, and its period low was -$172.9 million during Q1 2021.
- Over the past 3 years, Coherus Oncology's median EBIAT value was -$44.5 million (recorded in 2025), while the average stood at $14.3 million.
- In the last 5 years, Coherus Oncology's EBIAT slumped by 586.19% in 2021 and then skyrocketed by 642.87% in 2025.
- Coherus Oncology's EBIAT (Quarterly) stood at -$45.7 million in 2021, then fell by 28.75% to -$58.9 million in 2022, then slumped by 35.30% to -$79.7 million in 2023, then soared by 348.34% to $197.8 million in 2024, then rose by 6.47% to -$44.5 million in 2025.
- Its last three reported values are -$44.5 million in Q3 2025, $297.8 million for Q2 2025, and -$56.6 million during Q1 2025.